Table 3.
Oncologic results and outcomes from the 12 studies comparing TT vs TT/PND
| Study (LE) | No. of TT vs TT/PND | I131 (%) | pN1 (%) | Recurrence (%) TT vs TT/PND |
Pre-ablative negative Tg level (%) or means of Tg levels TT vs TT/PND (ng/mL) |
Undetectable final Tg (%) TT vs TT/PND or means of Tg levels TT vs TT/PND (ng/mL) |
|---|---|---|---|---|---|---|
| Lang et al. [17] (LE 2) | TT: 1,739 | 62 | – | 8.6 vs 4.7 | – | – |
| TT/PND: 1,592 | ||||||
| Wang et al. [28] (LE 4) | TT: 995 | – | – | 7.9 | – | – |
| TT/PND: 745 | 4.7 | |||||
| Central bilateral | ns | |||||
| Barczynski et al. [10] (LE 4) | TT: 282 | 48.4 | 30 | 13.1 | 89.4 | 1.8 ng/mL |
| TT/PND: 358 | 4.2 | 94.4 | 0.04 ng/mL | |||
| Central bilateral | p < 0.001 | p = 0.018 | p = 0.005 | |||
| Popadich et al. [13] (LE 4) | TT: 347 | 98 | 49 | 8.1 | – | 7.2 ng/mL |
| TT/PND: 259 | 5 | – | 1.9 ng/mL | |||
| Central bilateral 22 % | p = 0.11 | p = 0.025 | ns | |||
| Unilateral 78 % | ||||||
| Sywak et al. [36] (LE 4) | TT: 391 | 100 | 38 | 5.6 | – | 43 % |
| TT/PND: 56 | 3.6 | – | 72 % | |||
| Central unilateral | p = 0.001 | |||||
| Zuniga et al. [32] (LE 4) | TT: 130 | 70 | 82.3 | 19 vs 14 | – | – |
| TT/PND: 136 | ns | – | – | |||
| Central bilateral | ||||||
| Hartl et al. [12] (LE 4) | TT: 91 | 100 | 52 | 20 | 43 | 84 % |
| TT/PND: 155 | 7.7 | 65 | 93 % | |||
| Central bilateral + lateral ipsilateral |
p = 0.005 | p = 0.001 | p = 0.03 | |||
| Costa et al. [27] (LE 3) | TT: 118 | 61 | 46.8 | 7.6 vs 6.3 | – | – |
| TT/PND: 126 | ns | – | – | |||
| Central unilateral or bilateral | ||||||
| So et al. [35] (LE 4) | TT: 113 | 83 | 37 | 3.5 vs 1.7 | 2.24 ng/mL | 0.69 ng/mL |
| TT/PND: 119 | ns | 1.07 ng/mL | 0.44 ng/mL | |||
| Central bilateral | p < 0.022 | ns | ||||
| Raffaelli et al. [20] (LE 3) | TT: 62 | – | 35.5 | 0 vs 0.8 | – | – |
| TT/PND: 124 | ns | ns | – | |||
| Central unilateral or bilateral | ||||||
| Lang et al. [19] (LE 4) | TT: 103 | 67 | 54.9 | 2.9 vs 3.7 | 22.3 | <0.5 ng/mL |
| TT/PND: 82 | ns | 51.2 | <0.5 ng/mL | |||
| Central unilateral | p < 0.024 | ns | ||||
| Hughes et al. [18] (LE4) | TT:65 | 86 vs 92 | 62 | 4.6 | 15 | 77 % |
| TT/PND: 78 | 5.1 | 10 | 75 % | |||
| Central bilateral | ns | ns | ns | |||
| Moo et al. [16] (LE 4) | TT: 36 | 70 | 33.3 | 16.7 vs 4.4 | – | – |
| TT/PND: 45 | ns | – | – | |||
| Central bilateral |
LE level of evidence, TT total thyroidectomy, TT/PND total thyroidectomy with prophylactic neck dissection, Tg thyroglobulin